Close Menu

NEW YORK (GenomeWeb) – GenePOC announced today that its rapid molecular assay to detect group A Streptococcus has been granted clearance by the US Food and Drug Administration.

The test, which runs on GenePOC's Revogene instrument, is the third test from the Quebec City-based diagnostics developer to be FDA cleared. It uses throat swab samples and can report positive Strep A results in as little as 42 minutes, and negative results in 70 minutes without requirement for confirmation by bacterial culture, the firm said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.